Forum for Science, Industry and Business

First results from Ebola vaccine trials are promising

02.04.2015

The Tübingen University Hospital in conjunction with its partner site Centre de Recherche Medicales Lambaréné (CERMEL) has analysed data from the first 39 participants in its Phase I Ebola vaccine trial, being conducted as part of a World Health Organisation (WHO) initiated consortium.

The study is investigating the vaccine candidate rVSV-ZEBOV-GP developed by the Canadian Public Health Agency and produced by the US firm NewLink Genetics. More recently, it has been bought by Merck, who are supporting further Phase I as well as Phase II and III trials.

In the initial phase, two doses of the vaccine were tested in 39 participants in Lambarene, Gabon. Safety, tolerability and immunogenicity of the vaccine were assessed with very promising results.

In addition, a variety of doses of the vaccine were tested at collaborating sites internationally and the data are summarised in a paper published in the New England Journal of Medicine on the 1st April.

rVSV-ZEBOV-GP is a unique vaccine which uses a replicating virus in which the coat protein, recognised by the immune system, has been replaced with a coat protein from the Ebola virus (EBOV). The study in Lambaréné has shown that a single injection of this vaccine is well tolerated and generates a good immune response to EBOV.

The study in Lambaréné, headed by Principle Investigator Dr. Maxime Agnandji and Tübingen’s Professor Peter Kremsner is currently vaccinating further adults in an attemptto establish an optimal dose, and will begin vaccinating adolescents and children later this month.

The data from this site are vital for informing further clinical trials of the vaccine, licensure proceedings and how it will eventually be deployed in West Africa.

Die letzten 5 Focus-News des innovations-reports im Überblick:

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...